Table 1.
Basic information of eligible articles
| Reference | Year | Phase | Sample size | Histology | Treatment |
|---|---|---|---|---|---|
| Garon et al11 | 2015 | I | 495 | Advanced non-small-cell lung cancer | Pembrolizumab |
| Herbst et al26 | 2015 | II, III | 1,034 | Advanced non-small-cell lung cancer | Pembrolizumab and control therapy |
| Hua et al27 | 2016 | I | 67 | Melanoma | Pembrolizumab |
| Le et al17 | 2015 | II | 41 | Metastatic carcinoma | Pembrolizumab |
| Nghiem et al29 | 2016 | II | 26 | Merkel cell carcinoma | Pembrolizumab |
| Patnaik et al30 | 2015 | I | 32 | Solid tumors | Pembrolizumab |
| Ribas et al31 | 2016 | I | 655 | Advanced melanoma | Pembrolizumab |
| Ribas et al32 | 2015 | II | 540 | Ipilimumab-refractory melanoma | Pembrolizumab and control therapy |
| Robert et al33 | 2014 | I | 173 | Ipilimumab-refractory melanoma | Pembrolizumab |
| Robert et al34 | 2015 | III | 834 | Advanced melanoma | Pembrolizumab and control therapy |
| Karydis et al28 | 2016 | NA | 25 | Uveal melanoma | Pembrolizumab |
Abbreviation: NA, not applicable.